Ray Johnston’s goal in three years is for his band to sell out at the 1,600-seat House of Blues in Dallas. In eight years, he wants to pack the 6,400-seat Verizon Theatre in Grand Prairie, and by 2030, to play to tens of thousands of fans at Cowboys Stadium in Arlington. Mr. Johnston’s unmentioned goal, though, is to live another year after battling leukemia for the past seven…

Acute lymphoblastic leukemia, or ALL, is the most common form of childhood cancer. While most children treated for this disease survive, in a subgroup of patients the disease does not respond to treatment…

Micromet, Inc. (Nasdaq: MITI) today announced that data from a Phase 2 clinical trial of the Company’s lead product candidate blinatumomab in patients with minimal residual disease positive (MRD) acute lymphoblastic leukemia (ALL) were published in the May 16th on-line edition of the Journal of Clinical Oncology (JCO)…

YM BioSciences Inc. (NYSE Amex: YMI) (TSX: YM), reported updated interim results for the first 60 patients with high/intermediate-risk myelofibrosis who have completed a minimum of three cycles of treatment (12 weeks) in its ongoing Phase I/II multi-center study…

New research from the Swedish medical university Karolinska Institutet shows that hydroxyurea, one type of cytotoxic treatment for chronic myeloproliferative blood disorders, does not increase the risk of developing acute leukaemia, as had previously been suspected. Rather, it is the disease itself that mainly increases this risk…